

Department of Planning and Budget 2023 Fiscal Impact Statement

1. Bill Number: HB2233

House of Origin	<input checked="" type="checkbox"/>	Introduced	<input type="checkbox"/>	Substitute	<input type="checkbox"/>	Engrossed
Second House	<input type="checkbox"/>	In Committee	<input type="checkbox"/>	Substitute	<input type="checkbox"/>	Enrolled

2. Patron: Sickles

3. Committee: Committee Referral Pending

4. Title: Prescription drug price transparency; manufacturer reporting requirements.

5. Summary: Removes the requirement that a drug manufacturer submit to the Department of Health's contracted nonprofit data services organization all information included in the manufacturer's annual consolidation report on Securities and Exchange Commission Form 10-K or any other public disclosure in order for the manufacturer's prescription drug reporting obligations to be fully satisfied.

6. Budget Amendment Necessary: No.

7. No Fiscal Impact.

8. Fiscal Implications: This legislation would not have a fiscal impact on the Department of Health, the Department of Health Professions, or the Commonwealth.

9. Specific Agency or Political Subdivisions Affected: None.

10. Technical Amendment Necessary: No.

11. Other Comments: None.